X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8769) 8769
Book Review (1798) 1798
Publication (751) 751
Book Chapter (119) 119
Conference Proceeding (35) 35
Book / eBook (15) 15
Magazine Article (7) 7
Newsletter (6) 6
Dissertation (3) 3
Newspaper Article (3) 3
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7351) 7351
humans (5313) 5313
animals (3837) 3837
pharmacology & pharmacy (3240) 3240
prodrugs - therapeutic use (2158) 2158
prodrugs (2149) 2149
male (1982) 1982
female (1696) 1696
mice (1683) 1683
prodrug (1575) 1575
cancer (1436) 1436
prodrugs - pharmacology (1430) 1430
prodrugs - chemistry (1318) 1318
prodrugs - pharmacokinetics (1238) 1238
chemistry, medicinal (1154) 1154
prodrugs - administration & dosage (1123) 1123
rats (1065) 1065
oncology (994) 994
drug delivery systems (968) 968
drugs (952) 952
cell line, tumor (933) 933
prodrugs - metabolism (917) 917
chemistry, multidisciplinary (900) 900
pharmacokinetics (839) 839
biochemistry & molecular biology (838) 838
analysis (738) 738
in-vitro (723) 723
prodrugs - chemical synthesis (687) 687
chemotherapy (680) 680
adult (661) 661
middle aged (651) 651
antineoplastic agents - therapeutic use (631) 631
neoplasms - drug therapy (588) 588
administration, oral (585) 585
antineoplastic agents - pharmacology (577) 577
in-vivo (567) 567
nanoparticles (562) 562
dose-response relationship, drug (556) 556
therapy (546) 546
enzymes (534) 534
article (529) 529
tumors (528) 528
hydrolysis (527) 527
drug-delivery (504) 504
molecular structure (504) 504
care and treatment (498) 498
aged (496) 496
solubility (496) 496
chemistry, organic (482) 482
cells (480) 480
health aspects (480) 480
drug design (478) 478
antineoplastic agents - chemistry (446) 446
research (443) 443
mice, nude (442) 442
structure-activity relationship (438) 438
pharmacology/toxicology (433) 433
treatment outcome (433) 433
delivery (429) 429
drug therapy (428) 428
prodrugs - adverse effects (417) 417
derivatives (409) 409
vehicles (408) 408
medicine, research & experimental (405) 405
drug delivery (399) 399
cell survival - drug effects (397) 397
rats, sprague-dawley (389) 389
cytotoxicity (369) 369
expression (366) 366
metabolism (363) 363
tumor cells, cultured (361) 361
drug stability (358) 358
pharmacology (355) 355
toxicity (354) 354
mice, inbred balb c (343) 343
biotechnology & applied microbiology (339) 339
genetic therapy - methods (334) 334
doxorubicin (331) 331
kinetics (327) 327
antineoplastic agents - administration & dosage (322) 322
gene therapy (317) 317
apoptosis (314) 314
pharmacy (313) 313
hydrogen-ion concentration (312) 312
design (296) 296
xenograft model antitumor assays (295) 295
chromatography, high pressure liquid (290) 290
biological availability (289) 289
antineoplastic agents (286) 286
permeability (286) 286
time factors (282) 282
biomedicine (281) 281
clinical trials as topic (275) 275
activation (270) 270
disease models, animal (269) 269
antiviral agents - therapeutic use (265) 265
bioavailability (262) 262
antitumor-activity (259) 259
biochemistry, general (257) 257
abridged index medicus (256) 256
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8690) 8690
German (60) 60
Japanese (53) 53
French (44) 44
Russian (13) 13
Spanish (13) 13
Chinese (7) 7
Italian (7) 7
Polish (4) 4
Czech (3) 3
Swedish (3) 3
Dutch (2) 2
Portuguese (2) 2
Finnish (1) 1
Korean (1) 1
Norwegian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 03/2016, Volume 531, Issue 7594, pp. 381 - 385
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 20, pp. 2001 - 2015
Antiplatelet therapy with aspirin and a thienopyridine is a key component in the management of acute coronary syndromes. This trial compared a novel, potent... 
MEDICINE, GENERAL & INTERNAL | HIGH-RISK PATIENTS | PLATELET GLYCOPROTEIN IIB/IIIA | STENT THROMBOSIS | ACUTE MYOCARDIAL-INFARCTION | UNSTABLE ANGINA | PLACEBO-CONTROLLED TRIAL | ST-SEGMENT ELEVATION | ORAL ANTIPLATELET THERAPY | ASPIRIN | INTERVENTION | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Myocardial Infarction - epidemiology | Thiophenes - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Acute Coronary Syndrome - mortality | Male | Angioplasty, Balloon, Coronary - adverse effects | Ticlopidine - adverse effects | Female | Stroke - epidemiology | Aspirin - therapeutic use | Thrombosis - prevention & control | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Double-Blind Method | Kaplan-Meier Estimate | Purinergic P2 Receptor Antagonists | Piperazines - therapeutic use | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Acute Coronary Syndrome - drug therapy | Prodrugs - adverse effects | Acute Coronary Syndrome - therapy | Aged | Myocardial Infarction - prevention & control | Prodrugs - therapeutic use | Hemorrhage - chemically induced | Complications and side effects | Clopidogrel | Dosage and administration | Drug therapy | Coronary heart disease | Cardiovascular disease | Heart attacks | Angina pectoris | Acute coronary syndromes | Index Medicus | Abridged Index Medicus
Journal Article
Advanced Drug Delivery Reviews, ISSN 0169-409X, 09/2017, Volume 118, pp. 1 - 1
Journal Article
JAMA, ISSN 0098-7484, 02/2005, Volume 293, Issue 6, pp. 681 - 689
CONTEXT Ximelagatran, an oral direct thrombin inhibitor with a rapid onset of action and predictable antithrombotic effect, has the potential to be a simple... 
ORAL XIMELAGATRAN | ENOXAPARIN | MEDICINE, GENERAL & INTERNAL | KNEE REPLACEMENT | THERAPY | VENOUS THROMBOEMBOLISM | MELAGATRAN | INTRAVENOUS UNFRACTIONATED HEPARIN | ABSORPTION | INHIBITOR XIMELAGATRAN | SECONDARY PREVENTION | Prodrugs - administration & dosage | Recurrence | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Venous Thrombosis - complications | Heparin, Low-Molecular-Weight - therapeutic use | Warfarin - administration & dosage | Warfarin - therapeutic use | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Pulmonary Embolism - complications | Double-Blind Method | Venous Thrombosis - drug therapy | Venous Thrombosis - mortality | Anticoagulants - therapeutic use | Treatment Outcome | Azetidines - administration & dosage | Azetidines - therapeutic use | Benzylamines | Aged | Prodrugs - therapeutic use | Alanine Transaminase - metabolism | Heparin, Low-Molecular-Weight - administration & dosage | Clinical trials | Cardiac arrhythmia | Thrombolytic drugs | Medical treatment | Blood clots | Index Medicus | Abridged Index Medicus | Low-Molecular-Weight/administration & dosage/therapeutic use | Anticoagulants/administration & dosage/therapeutic use | Pulmonary Embolism/complications | Drug Therapy | MEDICIN OCH HÄLSOVETENSKAP | Alanine Transaminase/metabolism | Warfarin/administration & dosage/therapeutic use | 80 and over | Azetidines/administration & dosage/therapeutic use | Combination | Prodrugs/administration & dosage/therapeutic use | Venous Thrombosis/complications/drug therapy/mortality | Heparin | MEDICAL AND HEALTH SCIENCES
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 2004, Volume 109, Issue 25, pp. 3171 - 3175
Background-Although clopidogrel reduces the risk of cardiovascular episodes after coronary events and stenting, a substantial number of incidents continue to... 
clopidogrel | CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | myocardial infarction | PLATELET INHIBITION | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | ASPIRIN | platelets | Recurrence | Prospective Studies | Coronary Thrombosis - epidemiology | Follow-Up Studies | Ticlopidine - pharmacology | Ticlopidine - therapeutic use | Humans | Middle Aged | Epinephrine - administration & dosage | Male | Risk | Aspirin - administration & dosage | Myocardial Infarction - therapy | Epinephrine - therapeutic use | Biotransformation | Coronary Thrombosis - prevention & control | Platelet Aggregation Inhibitors - pharmacology | Female | Aspirin - therapeutic use | Platelet Aggregation - drug effects | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Stents | Drug Resistance | Purinergic P2 Receptor Antagonists | Coronary Restenosis - prevention & control | Treatment Outcome | Combined Modality Therapy | Ticlopidine - analogs & derivatives | Adenosine Diphosphate - pharmacology | Coronary Restenosis - epidemiology | Coronary Artery Disease - therapy | Myocardial Infarction - drug therapy | Smoking - epidemiology | Coronary Artery Disease - complications | Aged | Coronary Thrombosis - etiology | Myocardial Infarction - prevention & control | Prodrugs - therapeutic use | Adenosine Diphosphate - antagonists & inhibitors | Prodrugs - pharmacology | Peptides - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 26, pp. 2522 - 2533
Journal Article